News | November 14, 2022
Aurobindo Pharma Q2 FY23 revenue down 3.4%
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
The brand is now available pan-India through their distribution partner
The drug will be marketed under the brand name Molnaflu
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Subscribe To Our Newsletter & Stay Updated
